Clinical Trials

44 enrolled

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer

NCT06334757 2024-03-28

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

46 enrolled

Non-Squamous Non-Small Cell Lung Cancer

NCT06332287 2024-03-27

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis

25 enrolled

NSCLC

NCT06277674 2024-03-08

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05810350 2023-04-13

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT04396457 2023-03-23

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Lung Neoplasms

NCT05741021 2023-02-24

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04211090 2022-11-16

CAP-BRAIN

45 enrolled

CNS

Brain Neoplasms

NCT02436733 2022-11-07

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Other solid neoplasmThoracic

64 enrolled

Mesothelioma, Malignant

NCT05574998 2022-10-12

FTANLCNDG

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05507606 2022-08-19

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Carcinoma, Non-Small-Cell Lung

NCT04683965 2022-08-02

Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

27 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05458726 2022-07-26

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05448781 2022-07-07

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05430802 2022-06-24

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Carcinoma, Non-Small-Cell Lung

NCT02588781 2022-06-15

Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study

23 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03110484 2022-06-15

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

44 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05394233 2022-05-27

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

20 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT04989322 2021-12-08

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

46 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04405674 2021-11-22

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03830411 2021-11-08

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

76 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT03863483 2021-11-08

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

70 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT04943029 2021-09-02

NEOSUN

Carcinoma, Non-Small-Cell Lung

NCT04586465 2021-08-24

DYNAPET

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04982549 2021-08-06

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

35 enrolled

Unresectable Stage III NSCLC

NCT04713761 2021-01-26

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

15 enrolled

Mesothelioma, Malignant

NCT04706949 2021-01-13

Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04530227 2020-11-13

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04592666 2020-10-19

APPEAL

226 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

60 enrolled

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT04470076 2020-07-14

Neoafa

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

168 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02737774 2020-07-01

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

60 enrolled

Adenocarcinoma of Lung

NCT04453423 2020-07-01

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

90 enrolled

Non-squamous Non-small-cell Lung Cancer

NCT00276783 2020-03-05

Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

31 enrolled

CNSLymphoidSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Lymphoma, Neoplasm Metastasis, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT02725918 2020-02-12

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04094909 2020-02-07

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

186 enrolled

Staging IV NSCLC

NCT03656094 2019-12-09

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

98 enrolled

Non-small Cell Lung Cancer Metastatic

NCT04054531 2019-09-10

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

NCT03062800 2019-06-05

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

232 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03647956 2019-04-17

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Carcinoma, Non-Small-Cell Lung

NCT03374280 2019-03-28

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

178 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03778138 2018-12-19

ALTER-L025

51 enrolled

Non-squamous Cell Non-Small Cell Lung Cancer

NCT03706703 2018-10-17

Rh-Endostatin (Endostar®) Continuous Intravenous Infusion